Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Biomarin Pharmaceutical



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 2.1%. By the end of trading, Biomarin Pharmaceutical fell $0.72 (-1.0%) to $68.29 on average volume. Throughout the day, 1,653,487 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1,294,400 shares. The stock ranged in price between $66.90-$69.59 after having opened the day at $69.02 as compared to the previous trading day's close of $69.01. Other companies within the Drugs industry that declined today were:




), down 7.0%,

ProPhase Labs



), down 6.7%,

Mirati Therapeutics



TheStreet Recommends

), down 6.1% and

Aerie Pharmaceuticals



), down 5.8%.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $10.1 billion and is part of the health care sector. Shares are down 1.9% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Biomarin Pharmaceutical

as a


. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

On the positive front,

Idenix Pharmaceuticals



), up 17.0%,

SciClone Pharmaceuticals



), up 16.7%,




), up 14.0% and

Arrowhead Research Corporation



), up 13.6% , were all gainers within the drugs industry with




) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.